**Core Concept**
Dobutamine and dopamine are both inotropic agents used in cardiac failure, but they differ in receptor selectivity. Dobutamine primarily acts as a selective β₁-adrenergic receptor agonist, enhancing cardiac contractility without significant vasoconstriction, while dopamine has a broader receptor profile, including activation of dopamine D₁ receptors in the kidneys and peripheral vasculature.

**Why the Correct Answer is Right**
Dobutamine does not activate peripheral dopaminergic receptors (D₁ or D₂), unlike dopamine, which stimulates D₁ receptors in the kidneys and D₂ receptors in the periphery, leading to renal vasodilation and diuresis. This distinction is crucial in clinical use—dopamine can cause renal hypoperfusion at high doses, whereas dobutamine avoids this effect due to lack of dopaminergic activation. The absence of peripheral dopaminergic stimulation makes dobutamine safer in patients with renal impairment or shock.

**Why Each Wrong Option is Incorrect**
Option A: Dobutamine has poor blood-brain barrier penetrability, unlike dopamine, which crosses the BBB and has central effects.
Option B: Dobutamine causes tachycardia, but so does dopamine—this is not a distinguishing feature.
Option C: Dobutamine **does** activate β₁ receptors, and it is a potent β₁ agonist; thus, this statement is false.

**Clinical Pearl / High-Yield Fact**
Remember: **Dobutamine = β₁-selective → inotropy without renal effects; Dopamine = multi-receptor → vasoactive and renal effects.** Always consider renal perfusion when choosing between them in shock states.

✓ Correct Answer: D. It does not activate peripheral dopaminergic receptors